Alnylam to Webcast Presentations at Upcoming November Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Alnylam Pharma (ALNY) Issues Positive Update from Phase 2 OLE as ATTR Amyloidosis Treatment
November 3, 2015 7:44 AM ESTAlnylam Pharma (Nasdaq: ALNY) announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis). These new clinical data were presented at the 1st European Congress on Hereditary ATTR amyloidosis... More
